Hyperandrogenism, ovulatory dysfunction, and polycystic ovary syndrome with valproate versus lamotrigine

Annals of Neurology - Tập 64 Số 2 - Trang 200-211 - 2008
Martha J. Morrell1, Frances J. Hayes2, Patrick M. Sluss2, Judith Adams2, Mohit Bhatt3, Çiğdem Özkara4, Clay R. Warnock5, Jouko Isojärvi6,7
1Stanford University, Stanford and Neuropace, Mountain View, CA
2Massachusetts General Hospital, Boston, MA
3Jaslok Hospital and Kokilaben Dhirubhai Ambani Hospital, Mumbai, India
4İstanbul University, İstanbul, Turkey
5GlaxoSmithKline, Research Triangle Park, NC
6UCB Group, Research Triangle Park, NC
7University of Oulu, Oulu, Finland

Tóm tắt

AbstractObjectiveTo evaluate development of components of polycystic ovary syndrome (PCOS) and PCOS in women with epilepsy initiating valproate or lamotrigine therapy.MethodsFemale individuals with epilepsy and regular menstrual cycles were eligible for this prospective study. Participants were randomized to 12 months of valproate (n = 225) or lamotrigine (n = 222) therapy. Serum androgen levels were measured every 3 months. Urinary pregnanediol glucuronide levels were measured weekly for two 3‐month periods. The primary end point was development of PCOS components (ie, hyperandrogenism or ovulatory dysfunction). A post hoc analysis was conducted in women more than 2 years after menarche (177 lamotrigine, (HA) 186 valproate) to exclude OD the confounding effect of puberty.ResultsMore women in the valproate group than the lamotrigine group developed (OD) in the prospective (54% valproate, 38% lamotrigine; p = 0.010) and the post hoc (HA) analyses (36% valproate, 23% lamotrigine; p = 0.007). More women in the valproate group than the lamotrigine group developed PCOS (9 vs 2%; p = 0.007). Development of HA was more frequent with OD valproate than lamotrigine among those initiating treatment at age younger than 26 years (44% valproate, 23% lamotrigine; p = 0.002) but was similar if treatment was started at age 26 years or older (24% valproate, 22% lamotrigine).InterpretationDevelopment of HA occurred more frequently with valproate than lamotrigine, especially if medication was started at age younger than 26 years. Ann Neurol 2008;64:200–211

Từ khóa


Tài liệu tham khảo

10.1111/j.1528-1157.1980.tb04072.x

10.1001/archneur.1986.00520040029014

10.1111/j.1528-1157.1986.tb03605.x

10.1056/NEJM199311043291904

10.1002/ana.10391

10.1093/aje/kwh140

10.1016/S0889-8529(05)70045-1

10.1016/S0889-8529(05)70069-4

10.1007/BF03348013

Murialdo G, 1998, Effects of valproate, phenobarbital and carbamazepine on sex steroid setup in women with epilepsy, Clin Neuropharmacol, 21, 52

10.1002/1531-8249(199904)45:4<444::AID-ANA5>3.0.CO;2-6

10.1016/S1059-1311(03)00065-7

10.1016/S0002-9343(01)00806-3

10.1212/01.WNL.0000106942.35533.62

10.1016/S0920-1211(03)00085-8

10.1002/ana.410430406

10.1093/clinchem/37.6.838

10.1002/ajim.4700280611

10.1136/bmj.293.6543.355

Zawadski JK, 1992, Polycystic ovary syndrome, 377

Norman AW, 1997, Estrogens and progestins. Hormones, 361

10.1210/jc.83.9.3078

10.1210/jc.85.7.2434

Diamanti‐Kaundarakis E, 1999, A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile, J Clin Endocrinol Metab, 84, 4006, 10.1210/jcem.84.11.6148

10.1212/WNL.34.10.1389

10.1111/j.1528-1157.1988.tb03770.x

10.1212/WNL.57.3.440

10.1016/S0890-6238(02)00020-5

10.1046/j.1528-1157.2003.60702.x

10.1210/en.2003-0940

10.1016/j.biopsych.2005.10.017

10.1016/j.fertnstert.2003.10.004

Thông tin
Thông tin xuất bản

Annals of Neurology

Tập 64 Số 2

200-211

Thông tin tác giả